<DOC>
	<DOCNO>NCT02961608</DOCNO>
	<brief_summary>LCP-Tacro extended-release formulation tacrolimus design once-daily dose . Phase 1 study demonstrate great bioavailability twice-daily tacrolimus capsule new safety concern . - Stable kidney transplant patient safely convert Adoport® twice-daily LCP-Tacro® . - The great bioavailability LCP-Tacro once-daily dosing result similar ( AUC ) exposure , dose approximately 30 % less , total daily dose Adoport® . - LCP-Tacro provide slow drug release result flatter kinetics characterize significantly low peak-trough fluctuation . - CN major cellular target calcineurin inhibitor ( CNIs ) cyclosporine A ( CsA ) tacrolimus . The ability drug inhibit CN activity dependent bind respective immunophilins , cyclophilins A B CsA FKBP12 tacrolimus . - CN inhibition rate limit phenomenon . Over concentration tacrolimus correlate increase CN activity .</brief_summary>
	<brief_title>Conversion Pharmacodynamic Study Stable Renal Transplant Patients Receiving Tacrolimus Two Times Day New Formulation Tacrolimus - LCP Tacro - 1 Time Day .</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Adult patient ( ≥ 18 year ) . Receivers cadaveric renal graft live donor 6 month posttransplant evolution . Patients receive Prograf stable stable TAC trough concentration 510ng / ml noninterrupted oral dose least 10 day ( steady state condition ) . receive concomitant immunosuppressive medication allow : sodium mycophenolate mofetil corticosteroid . Subjects must willing give write informed consent test able consent . If subject give write informed consent independently , legal representative instead . Women childbearing age must undergo pregnancy test time inclusion accept use medically acceptable method contraception selection receive medication specify protocol . • Patients dialysis treatment rejection transplantation . Patients treat substance potential interaction TAC , particularly potent inhibitor CYP3A4 ( telaprevir , boceprevir , ritonavir , ketoconazole , voriconazole , itraconazole , telithromycin clarithromycin ) inducer CYP3A4 ( rifampin rifabutin ) . Patients participate another clinical trial treat investigational drug within 30 day prior inclusion . Patients liver disease . The patient donor current diagnosis history malignancy within past 5 year except carcinoma nonmetastatic basal squamous cell skin treat successfully . pregnant breastfeed woman woman childbearing age unless use reliable contraception . A pregnancy test perform screen end study . Receiver organ transplant kidney . The recipient bone marrow stem cell transplant . Recipients kidney donor ABO incompatible . Patients donor specific antiHLA antibody . Recipients kidney anticipate cold ischemia time ≥ 24 hour . Patients concomitant uncontrolled infection , systemic infection treatment , unstable medical condition could interfere study objective . Patients severe diarrhea , vomit , active peptic ulcer gastrointestinal disorder affect absorption TAC . Patients white blood cell count ≤ 2.8 x 109 / L unless absolute neutrophil count ( ANC ) ≥ 1.0 x 109 / L Patients platelet count ≤ 50 x 109 / L Patients level aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) exceed &gt; 3 time upper limit normal 30 day prior transplant procedure . Patients know hypersensitivity TAC excipients formulation Envarsus® . unable swallow study medication patient . Patients form current substance abuse , psychiatric disorder condition , investigator 's opinion , may invalidate communication investigator . Patients require high intake potassium potassiumsparing diuretic . Patients treated substance know nephrotoxic neurotoxic effect . positive hepatitis C virus ( HCVRNA positive ) / hepatitis B virus ( HBV DNA HBsAg positive ) receiver . positive human immunodeficiency virus ( HIVAb positive ) receiver . unable understand effect risk study , give informed consent write unwilling comply study protocol patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>